TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01630785

Intervention type: DEVICE
Intervention: Intraoperative Neurophysiological Monitoring IONM
Description: Intraoperative Neurophysiological Monitoring IONM device. Manufacturer: Inomed, Emmendingen, Germany
Study: NCT03055858

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADO II AS (PDA closure)
Description: Closure of PDA using Amplatzer Duct Occluder II Additional Sizes (ADO II AS).
Study: NCT01962636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenylate mofetil
Description: Mycophenylate mofetil (MMF) 3 gram/day IV/PO for patients who are ≥ 40 kg divided in 2 or 3 doses. Pediatric patient (\<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours beginning day -3.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical cord blood
Description: Pre-medications and UCB infusion will be per current institutional policies/guidelines. The infusion of the first UCB unit should begin within 15 minutes, and no later than 30 minutes after arrival on the Unit. If 2 units are used, both cords will be infused within 30-60 minutes of each other as deemed clinically safe by the BMT attending or designee.
Study: NCT03699345

Intervention type: DEVICE
Intervention: Transcatheter Aortic Valve Replacement (TAVR)
Description: TAVR with the Edwards CENTERA THV System and accessories
Study: NCT03075254

Intervention type: DEVICE
Intervention: fMRI for Spinal Cord Neuroimaging
Description: The subjects will be positioned supine and immobilized by means of a padded head support. The spinous process of the first thoracic vertebra (T1) will be aligned with the center of surface Neuro - coil. This coil will be employed for both transmission of radio-frequency (RF) pulses and detection of the magnetic resonance (MR) signal. A modified FLASH sequence will be employed to obtain Blood Oxygen Level Dependent (BOLD)-sensitive images of the spinal cord.

Intervention type: DEVICE
Intervention: fMRI for Spinal Cord Neuroimaging
Description: The subjects will be positioned supine and immobilized by means of a padded head support. The spinous process of the first thoracic vertebra (T1) will be aligned with the center of surface Neuro - coil. This coil will be employed for both transmission of radio-frequency (RF) pulses and detection of the magnetic resonance (MR) signal. A modified FLASH sequence will be employed to obtain Blood Oxygen Level Dependent (BOLD)-sensitive images of the spinal cord.
Study: NCT00666341

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rPhleum
Description: Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 2 (40 μg)
Study: NCT03075254

Intervention type: DEVICE
Intervention: fMRI for Spinal Cord Neuroimaging
Description: The subjects will be positioned supine and immobilized by means of a padded head support. The spinous process of the first thoracic vertebra (T1) will be aligned with the center of surface Neuro - coil. This coil will be employed for both transmission of radio-frequency (RF) pulses and detection of the magnetic resonance (MR) signal. A modified FLASH sequence will be employed to obtain Blood Oxygen Level Dependent (BOLD)-sensitive images of the spinal cord.
Study: NCT02694809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conjugated Estrogens/Bazedoxifene
Description: Given PO
Study: NCT01575288

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100g maltose 1/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose trehalose
Description: 100g 1/day
Study: NCT02005328

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tested product : DC161-DP0291
Description: Application of product in the mouth twice daily

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tested product : DC161-DP0292
Description: Application of product in the mouth twice daily

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tested product : DC161-DP0293
Description: Application of product in the mouth twice daily

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reference product: solution for oromucosal sprays
Description: Application of product in the mouth twice daily
Study: NCT02670213

Intervention type: DRUG
Intervention: recombinant factor XIII
Description: No treatment given.Patients will be treated according to routine clinical practice at the discretion of the treating physician.
Study: NCT03468543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine Hydrochloride MR Prototype Capsule Formulation A
Description: Memantine HCl MR capsule formulation will be administered orally in a single dose
Study: NCT02694809

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03668977

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortified balanced protein-energy.
Description: The exact form of this supplement will be selected in Phases one and two but its composition will be in conformance with the recommendations from the expert panel convened by the B\&MGF on nutritional supplementation in pregnancy (Expert Consultation, 2016). The calorie content will be approxmately 400 Kcal/day with approximately 14 g of protein.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortified balanced protein-energy.
Description: The exact form of this supplement will be selected in Phases one and two but its composition will be in conformance with the recommendations from the expert panel convened by the B\&MGF on nutritional supplementation in pregnancy (Expert Consultation, 2016). The calorie content will be approxmately 400 Kcal/day with approximately 14 g of protein.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortified balanced protein-energy.
Description: The exact form of this supplement will be selected in Phases one and two but its composition will be in conformance with the recommendations from the expert panel convened by the B\&MGF on nutritional supplementation in pregnancy (Expert Consultation, 2016). The calorie content will be approxmately 400 Kcal/day with approximately 14 g of protein.
Study: NCT03100019

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03468543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine Hydrochloride MR Prototype Capsule Formulation B
Description: Memantine HCl MR capsule formulation will be administered orally in a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine Hydrochloride MR Prototype Capsule Formulation C
Description: Memantine HCl MR capsule formulation will be administered orally in a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine Hydrochloride MR Prototype Capsule Formulation D
Description: Memantine HCl MR capsule formulation will be administered orally in a single dose
Study: NCT01084252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab SAR650984
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab SAR650984
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab SAR650984
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab SAR650984
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab SAR650984
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab SAR650984
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab SAR650984
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab SAR650984
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab SAR650984
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab SAR650984
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab SAR650984
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab SAR650984
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab SAR650984
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab SAR650984
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT00666341

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rPhleum
Description: Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 3 (80 μg)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rPhleum
Description: Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 4 (120 μg)
Study: NCT01837095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POL6326
Description: POL6326 will be given by i.v. infusion over 2 hours. Treatment will occur on days prior to, on the day of and on days after treatment with eribulin
Study: NCT03468543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine Hydrochloride MR Prototype Capsule Formulation E
Description: Memantine HCl MR capsule formulation will be administered orally in a single dose

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: MRI will be performed on specified days according to protocol

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: MRI will be performed on specified days according to protocol

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: MRI will be performed on specified days according to protocol
Study: NCT01249118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0973 IV Infusion
Description: IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0973 IV Infusion
Description: IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0973 IV Infusion
Description: IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0973 Oral Capsules
Description: Oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0973 Oral Capsules
Description: Oral dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDC-0973 Oral Capsules
Description: Oral dose.
Study: NCT04564118

Intervention type: DRUG
Intervention: Retrospective analysis of assigned treatment
Description: analysis of treatment assigned by physicians within routine clinical practice
Study: NCT04211805

Intervention type: DRUG
Intervention: Tenofovir Alafenamide 25 MG for arm (A)
Description: Tenofovir Alafenamide (TAF) will be provided, 25 mg Per Oral daily.

Intervention type: DRUG
Intervention: Tenofovir Disoproxil Fumarate 300mg for arm (B)
Description: Tenofovir Disoproxil Fumarate (TDF) will be provided, 300 mg Per Oral daily.
Study: NCT01728480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entolimod
Description: Given SC

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: Undergo IMRT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study: NCT04834765

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-based art therapy
Description: The researchers developed a novel MBAT intervention consisting of 10 easily reproducible, clay-based MBAT directives, administered through an online platform delivery strategy. By developing an MBAT intervention that uses an online delivery strategy, the researchers realized it may have the potential of decreasing demands placed on counseling centers.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Art-only
Description: The AO modules consist of an open-ended art-making exercise, with minimal direction. The AO intervention is designed as an 'art for art's sake' intervention with the focus on the art-making and less on outcome or product. Participants are asked to pull their ball of clay out and spend ten minutes creating a form from the clay to visually express their experience in the present moment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-only
Description: The MO modules consist of only the mindfulness practices from the ABM intervention. The participants to follow along with a five-minute light yoga sequence, where asanas (yoga postures) are cued with breath. Yoga, for the purposes of the study, is explicitly defined to participants as the unity of breath with body movement. Poses were chosen based on their accessibility to a variety of body types and abilities, and chosen because they are documented to aid in grounding, increased haptic awareness, lowered levels of stress and anxiety, and restoration.
Study: NCT00526877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Risperidone long-acting injectable 25 milligram (mg) or 37.5 mg or 50 mg will be administered intramuscularly (into a muscle) depending on Investigator's discretion every 2 weeks for 24 weeks.
Study: NCT02609698

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coroflex ISAR
Description: This stent platform has a thin-strut cobalt-chromiun alloy backbone, no polymer, microporous surface.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coroflex ISAR
Description: This stent platform has a thin-strut cobalt-chromiun alloy backbone, no polymer, microporous surface.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 months DAPT

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6 months DAPT
Study: NCT02268851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TGR-1202
Description: Capsules taken whole daily with water and with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TGR-1202
Description: Capsules taken whole daily with water and with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Capsules taken whole with water- Do not consume fish oil, vitamin E, grapefruit, or Seville oranges

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Capsules taken whole with water- Do not consume fish oil, vitamin E, grapefruit, or Seville oranges
Study: NCT03977610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga-68 PSMA ligand
Description: For PSMA PET/CT scan, the subject will have catheter(s) placed for intravenous administration of \[68Ga\]PSMA-11. Subjects will receive a single intravenous bolus of 2-5 mCi \[68Ga\]PSMA-11 and received PET/CT scan 60 minutes later. Patient will underwent two times of PSMA-11 PET/CT scans before and under androgen deprivation therapy within a 10-14 weeks interval.
Study: NCT04428593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treamid 5 mg
Description: The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treamid 15 mg
Description: The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treamid 50 mg
Description: The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The volunteers received the study drug once, and then continued daily intake for 14 days after a 6-day break.
Study: NCT03813251

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ForConti Contix Fecal Incontinence Management System (FIMS)
Description: Use the device for up to 12 hours per use for 4 weeks
Study: NCT04023474

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet Rich Fibrin (PRF) Application
Description: Platelet Rich Fibrin application to flap defect.
Study: NCT03614780

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 30 minutes outdoors
Description: Participants were asked to add an additional 30 minutes of time spent outdoors during the last 5 days of participation
Study: NCT02916771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Oral, proteasome inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral, immunomodulatory agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral, steroid
Study: NCT02125474

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [177Lu] DOTA-TATE
Description: We have designed a one-arm phase II prospective sequential clinical trial to assess the therapeutic efficacy of 177-Lu-\[DOTA 0, Tyr 3\] octreotate (177-Lu- DOTATATE) applied intravenously in three separate doses to patients with inoperable progressive WDNET.
Study: NCT03092804

Intervention type: PROCEDURE
Intervention: ventriculo-peritoneal shunting
Description: A mainstream therapy for NPH. It involves the device of CSF flow control of shunts and accessories(CFDA(I)20143665605)
Study: NCT01208831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE225
Study: NCT04535167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07304814
Description: PF-07304814 is an anti-viral, formulated for intravenous delivery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be formulated for intravenous delivery
Study: NCT02133014

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic-assisted percutaneous catheter drainage
Description: Removing necrotic pancreatic organizations and putting the catheter around the region of pancreas.After the surgery,patient's cavity are continuously douched by catheter using 0.5% 5-fluorouracil normal saline
Study: NCT02285959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study: NCT03329781

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BCM-95
Description: Consuming 1 capsule of BCM-95 per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Consuming 1 placebo capsule per day
Study: NCT03177915

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hylase
Description: median nerve hydro-dissection using Hyalase + 10 cc saline injection
Study: NCT02133014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% 5-fluorouracil normal saline
Description: On the one hand,0.5% 5-fluorouracil normal saline directly inhibit DNA synthesis of pancreatic acinar cells which result in the synthesis of amylopsin of and trypsase is restrained.On the other hand,it can induce pancreatic cells apoptosis and alleviate pancreatic necrosis.
Study: NCT01596543

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: partial and complete sleep deprivation
Description: The subjects will visit our labs 4 times. The second visit will be used as the experimental control. During the third and fourth visits the subject will go through an exercise heat tolerance test and a measurement of their physiological efficiency after a partial and complete sleep deprivation, respectively.
Study: NCT04387760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: 400mg BID PO day 1 then 200mg BID PO from day 2 to day 10.~In addition to Hydroxychloroquine all patients will receive the standard care (according to local Bahrain COVID19 guidelines). Any patient who is fit for discharge, can be discharged and medications will be stopped on discharge.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir
Description: 1600mg BID PO day 1600mg BID PO day 2 to day 10.~In addition to Favipiravir all patients will receive the standard care (according to local Bahrain COVID19 guidelines). Any patient who is fit for discharge, can be discharged and medications will be stopped on discharge.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine care for COVID-19 patients
Description: Supportive care according to local guidelines

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine care for COVID-19 patients
Description: Supportive care according to local guidelines

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine care for COVID-19 patients
Description: Supportive care according to local guidelines
Study: NCT01487473

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-Based Stress Reduction
Description: An 8-week structured group program that was developed to improve psychological and physical symptoms associated with pain. It incorporates a variety of mindfulness meditation exercises including mindful yoga, sitting meditation, and body scan to facilitate attention, acceptance, and awareness of one's experiences.
Study: NCT02352922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine
Description: pre-incision infiltration with liposomal bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl
Description: pre-incision infiltration with bupivacaine HCl